GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Themis Medicare Ltd (BOM:530199) » Definitions » Debt-to-EBITDA

Themis Medicare (BOM:530199) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Themis Medicare Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Themis Medicare's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Themis Medicare's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Themis Medicare's annualized EBITDA for the quarter that ended in Dec. 2023 was ₹560 Mil. Themis Medicare's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Themis Medicare's Debt-to-EBITDA or its related term are showing as below:

BOM:530199' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.72   Med: 2.24   Max: 14.1
Current: 1.26

During the past 13 years, the highest Debt-to-EBITDA Ratio of Themis Medicare was 14.10. The lowest was 0.72. And the median was 2.24.

BOM:530199's Debt-to-EBITDA is ranked better than
57.88% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.705 vs BOM:530199: 1.26

Themis Medicare Debt-to-EBITDA Historical Data

The historical data trend for Themis Medicare's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Themis Medicare Debt-to-EBITDA Chart

Themis Medicare Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.10 2.16 1.43 0.72 1.02

Themis Medicare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.62 - 1.24 -

Competitive Comparison of Themis Medicare's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Themis Medicare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Themis Medicare's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Themis Medicare's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Themis Medicare's Debt-to-EBITDA falls into.



Themis Medicare Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Themis Medicare's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(639.297 + 284.455) / 909.999
=1.02

Themis Medicare's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 559.964
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Themis Medicare  (BOM:530199) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Themis Medicare Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Themis Medicare's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Themis Medicare (BOM:530199) Business Description

Traded in Other Exchanges
Address
Swami Vivekanand Road, 11/12, Udyog Nagar Industrial Estate, Goregaon (West), Mumbai, MH, IND, 400 104
Themis Medicare Ltd is an Indian based company engaged in the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India and also has a presence in the international market. Its product categories include Anti Malarial, CCD products, Nutritional Gummies, and Candy and Other Products such as OD-LM, Dexem, Medzol and Tazowin.

Themis Medicare (BOM:530199) Headlines

No Headlines